Highest-materiality recent filing
Selling stockholders (Warburg Pincus & GTCR affiliates) sold 31,838,253 shares at $15.168 per share.
Sotera Health reports Q1 2026 results and announces CEO transition
Q1 net revenues up 10.0% (6.5% constant currency); net income $27M vs loss $13M in prior year.
Sotera Health selling stockholders launch 25M-share secondary offering at $15.27 each
Selling stockholders sold 25 million shares at $15.27 per share; company receives no proceeds.
Sotera Health reports 2025 record revenue up 5.7% to $1.164B; guided 2026 growth 5-6.5%
2025 net revenue $1.164B (+5.7% YoY), net income $78M ($0.27 EPS) vs $44M ($0.16).
Sotera Health expects FY2025 revenue >$1.16B, up at least 5.5% YoY
Revenue expected to exceed $1.16 billion for full-year 2025, a YoY increase of at least 5.5% (5.0% constant-currency).
Sotera Health selling stockholders to sell 30M shares at $15.651 each
Underwriting agreement signed Nov 6, 2025 for 30M shares at $15.651/share via Goldman Sachs.
Sotera Health Q3 net revenues +9.1% to $311M; adj EBITDA +12.2%; raises 2025 guidance
Q3 net revenues rose 9.1% to $311M; net income $48M ($0.17 diluted EPS) vs $17M ($0.06) a year ago.
Sotera Health refinances $1.423B term loans, cuts interest margin by 0.50%
Amendment No. 6 reduces term loan interest spread by 0.50% to SOFR + 2.50% (0.00% floor).
Sotera Health selling stockholders sell 20M shares in secondary offering at $15.111/share
Selling stockholders sold 20,000,000 shares of common stock at $15.111 per share.
Sotera Health Q2 revenue up 6.4% to $294M; Adj EBITDA +9.8% to $151M; raises FY outlook
Q2 net revenues $294M (+6.4% YoY); constant currency +6.0%; net income $8M ($0.03 diluted EPS).
Sotera Health subsidiary Sterigenics settles 129 EO claims for $34M
Sterigenics enters binding term sheet to resolve 129 ethylene oxide (EO) claims for $34,000,000.
Sotera Health Q1 net loss $13M includes $31M EO settlement; Adj EBITDA up 8.8%
Net revenues $255M, up 2.6% YoY (4.4% constant currency). Sterigenics segment $170M.
Sotera Health's Sterigenics settles 97 EO claims for $30.9M
Settlement covers 97 ethylene oxide claims related to former Willowbrook, IL facility.
Sotera Health FY2024 revenue up 4.9% to $1.10B; net income down to $44M; provides 2025 outlook
Q4 net revenues down 6.5% to $290M; net income $12M ($0.04 EPS) vs $39M ($0.14 EPS) in Q4 2023.
Sotera Health Q3 net rev $285M (+8.5% YoY); net income $17M vs loss $14M; reaffirms FY outlook
Q3 net revenues $285M, up 8.5% YoY (8.9% constant currency); net income $17M ($0.06 diluted) vs net loss $14M in Q3 2023.
Sotera Health insider selling: 25M shares sold at $15.03; director Donnini resigns
Selling stockholders sold 25M shares at $15.03/share; company received no proceeds.
Sotera Health Q2 net revenue up 8.3% to $277M; adj. EBITDA up 6.9% to $137M
Net income $9M ($0.03 diluted) vs $24M ($0.08) in Q2 2023; decline due to debt refinancing charges.
Closed $1.509B Term Loan B (SOFR+3.25% or ABR+2.25%, 0% floor) and $750M 7.375% senior secured notes, both due 2031.
Sotera Health subsidiary prices $750M 7.375% senior secured notes due 2031 to refinance term loans
SHH priced $750M aggregate principal of 7.375% senior secured notes due 2031.
Sotera Health Q1 revenue up 12.5% to $248M; net income $6M; reaffirms 2024 outlook
Q1 net revenues $248M (+12.5% YoY); net income $6M ($0.02 diluted EPS) vs $3M ($0.01) in Q1 2023.
Sotera Health Q1 net rev up 12.5% to $248M; Adj EBITDA up 13.7%; reaffirms 2024 outlook
Q1 net rev $248M (+12.5% YoY); net income $6M ($0.02 EPS) vs $3M ($0.01) YoY.
Sotera Health refinances revolver to 2029; selling shareholders sell 28.75M shares
Amended credit agreement: new $83M revolver commitments, $37.5M additional LC commitments; total revolver unchanged at $423.75M.
Sotera Health reports 2023 revenue $1.05B (+4.5%); net income $51M; 2024 outlook 4-6% growth
2023 net revenues $1.05B (+4.5% YoY); net income $51M vs loss of $234M in 2022.
Sotera Health subsidiaries settle 79 EO claims for $35M; payments expected Jan 2024
Settling defendants pay $35M to resolve 79 ethylene oxide exposure claims from Sterigenics' Atlanta operations.
Sotera Health settles 79 Georgia EO claims for $35M; trial stayed pending
Subsidiaries Sotera Health LLC and Sterigenics U.S. LLC enter binding term sheet to settle 79 EO exposure claims.
Sotera Health Q2 net revenue $255M (-4% YoY), net income $24M; cuts full-year outlook
Q2 net revenues $255M, down 4% YoY; net income $24M ($0.08 diluted EPS) vs $30M ($0.11) in Q2 2022.
Sotera Health releases $408M settlement funds for ethylene oxide claims; claims dismissed
On June 30, 2023, ~$408M settlement funds were released from escrow for January 2023 settlements.
Sotera Health appoints Jonathan M. Lyons as CFO, effective June 26, 2023
Lyons succeeds Interim CFO Michael Biehl, will lead finance and accounting.
Sotera Health completes opt-in for $408M EO settlement; 99.7% of eligible claimants join
879 of 882 eligible claimants opted into the January 2023 ethylene oxide settlement.
Sotera Health Q1 2023 revenue falls 7% to $221M; net income drops to $3M; reaffirms 2023 outlook
Net revenues $221M, down 6.8% YoY; constant currency down 5.3%, driven by Nordion Cobalt-60 harvest timing.
Sotera Health enters $408M settlement agreements for EO claims at Willowbrook facility
Definitive Master Settlement Agreements signed with Plaintiffs' Executive Committee representing over 870 claimants.
Sotera Health Q4 net loss $320M on $408M legal reserve; provides 2023 outlook of 5-9% growth
Q4 net revenues $252M (+4% YoY); net loss $320M ($1.14/share) vs net income $36M in Q4 2021.
Sotera Health closed $500M Term Loan B, upsized from previously announced $425M.
Reaffirms 2022 net revenue guidance of $995M-$1.005B and Adjusted EBITDA of $500M-$510M.
the Board appointed Mr. Petras to serve as Executive Chairman of the Board ("Executive Chairman"), as of the Effective Date.
the Board, at the recommendation of the Nominating and Corporate Governance Committee, appointed Alton Shader to serve as Chief Executive Officer of the Company ("CEO") and a Class II director of the Board, effective as of May 26, 2026
appointed Alton Shader to serve as Chief Executive Officer of the Company ("CEO") and a Class II director of the Board
On September 6, 2024, David A. Donnini, one of GTCR’s designees, notified the Company that, consistent with this decrease, he wished to resign as a director.
On July 31, 2024, the Board of Directors (the “Board”) of Sotera Health Company (the “Company”) increased the size of the Board from eleven directors to twelve directors and appointed Christopher A. Simon as a Class III director of the Board, effective August 1, 2024.
On November 13, 2023, the Board of Directors (the “Board”) of Sotera Health Company (the “Company”) increased the size of the Board from ten to eleven and appointed Karen A. Flynn to serve as a director of the Company effective November 13, 2023.
On June 26, 2023, Sotera Health Company (the "Company") announced the appointment of Jonathan M. Lyons as Senior Vice President and Chief Financial Officer ("CFO") of the Company, effective June 26, 2023.
Mr. Lyons, age 46, who succeeds Michael F. Biehl as the Company's Interim CFO
On October 12, 2022, the Board appointed Robert B. Knauss to serve as a director of the Company, effective October 12, 2022.
On October 7, 2022, Stephanie M. Geveda notified Sotera Health Company (the “Company”) of her resignation as a director of the Company, effective October 7, 2022, in connection with her departure from Warburg Pincus LLC (“Warburg Pincus”).
Effective October 1, 2022, Mr. Matthew Klaben, Deputy General Counsel, will serve as Interim Senior Vice President, General Counsel and Secretary of the Company.
accepted Terrence Hammons’ resignation from his position as Senior Vice President, General Counsel and Secretary of the Company for personal reasons.
Max materiality 0.85 · Median 0.65 · Most common event earnings